Johnson & Johnson will resume the limited market release of VARIPULSE in the United States after a comprehensive ...

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter ...

To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Johnson & Johnson (NYSE: JNJ) announced on Friday that it is set to recommence the limited market release of its VARIPULSE™ devices in the United States. The de ...

Johnson & Johnson is relaunching sales of a promising heart-rhythm device after a safety scare, but with a new warning for doctors that analysts say could hamper its market potential ...

J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...

Johnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial ...

Johnson & Johnson resumes US market release of Varipulse heart device after confirming its safety. The Trump administration revises the number of layoffs at NIH to 1,165, slightly down from earlier ...